Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
ACTIVE_NOT_RECRUITING
Status
Conditions
- Metastatic Esophageal Adenocarcinoma
- Metastatic Esophageal Squamous Cell Carcinoma
- Metastatic Gastroesophageal Junction Adenocarcinoma
- Recurrent Esophageal Adenocarcinoma
- Recurrent Esophageal Carcinoma
- Recurrent Esophageal Squamous Cell Carcinoma
- Recurrent Gastroesophageal Junction Adenocarcinoma
- Stage IV Esophageal Cancer AJCC v7
Interventions
- BIOLOGICAL: Cixutumumab
- OTHER: Laboratory Biomarker Analysis
- DRUG: Paclitaxel
- OTHER: Pharmacological Study
Sponsor
National Cancer Institute (NCI)